Yes it is a good looking presentation deck right before the TPIV annual meeting, should get new and existing retail investors "excited". Heaven forbid if you are on the sidelines better get in now and buy shares before it is too late, this is great "Power-Point", great promotion.
Only problem, this is "ALL TALK" / "NO ACTION". This is the same old story heavily promoted for several years "here is what we are doing" but "we have never delivered on it for several years". We never executed on any presentation and never delivered and reported any real progress, data and/or material committments to date, always late on everything, full of mistakes, but believe TPIV now, TPIV has another great presentation on the website. In the absence od data need credibility, there is no credibility here. Let's recap recent history:
1. TRIBLive interview Wilson stated "TapImmune may have to do further Phase 2 studies before the pivotal Phase 3 studies that would allow licensure of the vaccine(s) over the next several years". This is first time I ever heard this, looks like Wilson is telegraphing more Phase 2 trials with a subtle comment so he does not get in trouble (kind of slimy). There goes the $10 Million cash but is it $10 Million, TPIV has millions in Accounts Payable at present, just how much available cash does TPIV have?
2. Where is the MAYO Paper for Phase 1 Long Term Results, you know the study that had 10 patients and is not statistically significant? Are the immune responses really durable versus competition? Are the other MAYO/DOD sponsored trials at risk until the paper is published and vetted within the Industry - YES. Is the DOD dealing with potential budget cuts - YES. Does the MAYO Phase 1 paper need to be compelling to maintain DOD funds and MAYO trials - YES. Is MAYO going to publish a paper or not, and where is it and when? Wilson stated "soon" several weeks ago, it appears he is late again.
3. AZN now has a combination maintenance therapy for ovarial cancer with Merck and it does not involve Durvamulab/TPIV 200. AZN has recent trial disappointments with Durvalumab which create much greater uncertainty for the TPIV combination trial with AZN/MSK.
4. Continued turnover at TapImmune delaying schedule and costing more money. Wilson can not maintain a staff, however, can hire someone to make a hell of a presentation.
5. Another round of disappointing financing creating significant dilution and all but capping near to intermediate term share price gains at current price or lower.
6. TPIV200 FDA trial amendment to make trial statistically significant and increase coverage, both sould have been addressed prior to initiating trials. Continuing mistakes made by Wilson and TPIV, they are like a hamster on a hamster wheel, running but never getting anywhere.
7. No action by TPIV BOD to respond to poor performance of TPIV management like Wilson. There is a questionable relationship and business between TPIV Management, some TPIV BOD and former employees at Iroquios and related companies. A similar relationship and potential legal action outcome was outlined in a Seeking Alpha article on the stock Neurotrope (NTRP). The article mentioned TPIV. Also, there has been "talk" of investors manipulating stock price, pushing TPIV share price lower resulting in significant reduction in strike price for current investor warrants. This was communicated to Wilson several times by a shareholder. Did large investors dump shares to suppress share price and then have strike prices for warrants reduced? Why aren't large investors upset at present? As a result, why isn't Wilson terminated, maybe it is because initial investors sold shares to cover their initial investment while realizing a lower strike price for warrants, thereby lowering overall acquisition cost and related risk.
In summary, great presentation, a hallmark of TPIV, we need real progress and date. In the absence of real data and progress you need to have someone at TapImmune that is credible, I am not sure if we have too many people at Tapimmune who are credible at present and some due to questionable behavior need to leave now. Do not let these guys pump you up too much, buy TPIV at an atractive price lower than where it is now not higher until we have something real and we get credible manafement. GLTA
